Brief: Mesoblast Posts Quarter Revenue From Cell Therapy Products $20.6 Million
20/10/2025 02:23
Oct 20 (Reuters) - Mesoblast Ltd MSB.AX: QUARTERLY ACTIVITIES/APPENDIX 4C CASH FLOW REPORT QUARTER REVENUE FROM CELL THERAPY PRODUCTS US$20.6 MILLION Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil